1. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. Issue 12 (8th September 2019) Authors: Perkovic, Vlado; Koitka-Weber, Audrey; Cooper, Mark E; Schernthaner, Guntram; Pfarr, Egon; Woerle, Hans J; von Eynatten, Maximilian; Wanner, Christoph Journal: Nephrology dialysis transplantation Issue: Volume 35:Issue 12(2020) Page Start: 2103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. (July 2015) Authors: McGill, Janet B; Yki-Järvinen, Hannele; Crowe, Susanne; Woerle, Hans-Juergen; von Eynatten, Maximilian Journal: Diabetes & vascular disease research Issue: Volume 12:Number 4(2015:Jul.) Page Start: 249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial. Issue 12 (10th September 2020) Authors: Wanner, Christoph; Inzucchi, Silvio E.; Zinman, Bernard; Koitka‐Weber, Audrey; Mattheus, Michaela; George, Jyothis T.; von Eynatten, Maximilian; Hauske, Sibylle J. Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 12(2020) Page Start: 2335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D™ trial. (November 2015) Authors: Groop, Per-Henrik; Cooper, Mark E; Perkovic, Vlado; Sharma, Kumar; Schernthaner, Guntram; Haneda, Masakazu; Hocher, Berthold; Gordat, Maud; Cescutti, Jessica; Woerle, Hans-Juergen; von Eynatten, Maximilian Journal: Diabetes & vascular disease research Issue: Volume 12:Number 6(2015:Nov.) Page Start: 455 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Issue 12 (December 2020) Authors: McGuire, Darren K; Zinman, Bernard; Inzucchi, Silvio E; Wanner, Christoph; Fitchett, David; Anker, Stefan D; Pocock, Stuart; Kaspers, Stefan; George, Jyothis T; von Eynatten, Maximilian; Johansen, Odd Erik; Jamal, Waheed; Mattheus, Michaela; Elsasser, Ulrich; Hantel, Stefan; Lund, Søren S Journal: Lancet Issue: Volume 8:Issue 12(2020) Page Start: 949 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Issue 8 (August 2017) Authors: Cherney, David Z I; Zinman, Bernard; Inzucchi, Silvio E; Koitka-Weber, Audrey; Mattheus, Michaela; von Eynatten, Maximilian; Wanner, Christoph Journal: Lancet Issue: Volume 5:Issue 8(2017) Page Start: 610 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials. Issue 1 (16th April 2014) Authors: Davidson, Jaime A; Lajara, Rosemarie; Aguilar, Richard B; Mattheus, Michaela; Woerle, Hans-Juergen; von Eynatten, Maximilian Journal: BMJ open diabetes research and care Issue: Volume 2:Issue 1(2014) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial. Issue 11 (26th August 2019) Authors: Ledesma, Gilbert; Umpierrez, Guillermo E.; Morley, John E.; Lewis‐D'Agostino, Diane; Keller, Annett; Meinicke, Thomas; van der Walt, Sandra; von Eynatten, Maximilian Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 11(2019) Page Start: 2465 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials. Issue 5 (3rd September 2015) Authors: Thrasher, James; Kountz, David S.; Crowe, Susanne; Woerle, Hans-Juergen; von Eynatten, Maximilian Journal: Postgraduate medicine Issue: Volume 127:Issue 5(2015) Page Start: 419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials. Issue 5 (July 2015) Authors: Thrasher, James; Kountz, David S.; Crowe, Susanne; Woerle, Hans-Juergen; von Eynatten, Maximilian Journal: Postgraduate medicine Issue: Volume 127:Issue 5(2015) Page Start: 419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗